1 week Ago By ABMN Staff
Shares of Agilent Technologies, Inc. ( NYSE:A – Get Free Report ) have received an average rating of “Hold” from the fifteen brokerages that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating and eight have assigned a buy rating to the company.
The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $141.60. A number of equities analysts recently commented on the stock.
Barclays lifted their target price on shares of Agilent Technologies from $125.00 to $135.00 and gave the stock an “underweight” rating in a research report on Friday, August 23rd.
Wells Fargo & Company initiated coverage on Agilent Technologies in a report on Tuesday, August 27th. They set an “overweight” rating and a $157.00 target price for the company.
JPMorgan Chase & Co. decreased their price target on Agilent Technologies from $165.00 to $155.
00 and set an “overweight” rating on the stock in a research note on Thursday, May 30th. Jefferies Financial Group reissued a “hold” rating and set a $135.00 price objective (down previously from $152.
00) on shares of Agilent Technologies in a research note on Monday, June 3rd. Finally, Bank of America lifted their target price on shares of Agilent Technologies from $140.00 to $147.
00 and gave the stock a “neutral” rating in a research note on Thursday, August 22nd. Check Out Our Latest Research Report on Agilent Technologies Insider Activity at Agilent Technologies Institutional Investors Weigh In On Agilent Technologies Hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc.
raised its holdings in Agilent Technologies by 18.2% in the 1st quarter. Vanguard Group Inc.
now owns 29,884,345 shares of the medical research company’s stock worth $4,348,471,000 after purchasing an additional 4,605,228 shares during the period. Massachusetts Financial Services Co. MA raised its stake in shares of Agilent Technologies by 5.
7% in the second quarter. Massachusetts Financial Services Co. MA now owns 15,064,660 shares of the medical research company’s stock worth $1,952,832,000 after buying an additional 809,149 shares during the period.
Price T Rowe Associates Inc. MD lifted its position in shares of Agilent Technologies by 13.9% during the 1st quarter.
Price T Rowe Associates Inc. MD now owns 8,542,054 shares of the medical research company’s stock valued at $1,242,956,000 after buying an additional 1,042,926 shares in the last quarter. Norges Bank bought a new position in shares of Agilent Technologies during the 4th quarter valued at approximately $509,904,000.
Finally, Van ECK Associates Corp increased its holdings in Agilent Technologies by 0.7% in the 2nd quarter. Van ECK Associates Corp now owns 2,793,189 shares of the medical research company’s stock worth $362,081,000 after acquiring an additional 18,205 shares in the last quarter.
Hedge funds and other institutional investors own 87.42% of the company’s stock. Agilent Technologies Stock Performance Shares of Agilent Technologies stock opened at $137.
20 on Friday. Agilent Technologies has a 12 month low of $96.80 and a 12 month high of $155.
35. The business’s fifty day simple moving average is $135.62 and its 200 day simple moving average is $139.
08. The firm has a market capitalization of $40.03 billion, a P/E ratio of 32.
43, a price-to-earnings-growth ratio of 6.63 and a beta of 1.05.
The company has a current ratio of 1.78, a quick ratio of 1.37 and a debt-to-equity ratio of 0.
36. Agilent Technologies ( NYSE:A – Get Free Report ) last issued its quarterly earnings data on Wednesday, August 21st. The medical research company reported $1.
32 EPS for the quarter, beating the consensus estimate of $1.26 by $0.06.
Agilent Technologies had a net margin of 21.75% and a return on equity of 25.26%.
The company had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.56 billion.
During the same quarter in the previous year, the company earned $1.43 earnings per share. Agilent Technologies’s revenue for the quarter was down 5.
6% on a year-over-year basis. As a group, analysts anticipate that Agilent Technologies will post 5.24 EPS for the current year.
Agilent Technologies Company Profile ( Get Free Report Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.
Further Reading Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter ..
